

Appl. No. 10/011,860

Amdt.AF dated May 6, 2005

Reply to Final Office Action of March 9, 2005

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-48. (Cancelled).

49. (Previously Presented) A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and for providing anti-bradycardia pacing energy to the heart, the method comprising:

generating anti-bradycardia pacing energy;

storing the anti-bradycardia pacing energy; and

delivering the anti-bradycardia pacing energy to the patient's heart;

wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately 25 volts and approximately 50 volts.

50. (Previously Presented) The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately .1 volts and approximately 100 volts.

51. (Previously Presented) The method of claim 50, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately .1 volts and approximately 25 volts.

52. (Previously Presented) The method of claim 50, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately 25 volts and approximately 50 volts.

Appl. No. 10/011,860

Amdt.AF dated May 6, 2005

Reply to Final Office Action of March 9, 2005

53. (Previously Presented) A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and for providing anti-bradycardia pacing energy to the heart, the method comprising:

generating anti-bradycardia pacing energy;

storing the anti-bradycardia pacing energy; and

delivering the anti-bradycardia pacing energy to the patient's heart;

wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately 50 volts and approximately 75 volts.

54. (Previously Presented) A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and for providing anti-bradycardia pacing energy to the heart, the method comprising:

generating anti-bradycardia pacing energy;

storing the anti-bradycardia pacing energy; and

delivering the anti-bradycardia pacing energy to the patient's heart;

wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is between approximately 75 volts and approximately 100 volts.

55. (Previously Presented) A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathoracic blood vessels and for providing anti-bradycardia pacing energy to the heart, the method comprising:

generating anti-bradycardia pacing energy;

storing the anti-bradycardia pacing energy; and

delivering the anti-bradycardia pacing energy to the patient's heart;

Appl. No. 10/011,860

Amdt. AF dated May 6, 2005

Reply to Final Office Action of March 9, 2005

wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is between 1 millisecond and approximately 40 milliseconds.

56. (Previously Presented) The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is between approximately 2 milliseconds and approximately 10 milliseconds.

57. (Previously Presented) The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is between approximately 10 milliseconds and approximately 20 milliseconds.

58. (Previously Presented) The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is between approximately 20 milliseconds and approximately 30 milliseconds.

59. (Previously Presented) The method of claim 55, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is between approximately 30 milliseconds and approximately 40 milliseconds.

60. (Original) The method of claim 49, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is either positive or negative in polarity.

61. (Previously Presented) The method of claim 60, wherein the positive voltage portion has a tilt of between approximately 5% and approximately 95%.

62. (Original) The method of claim 61, wherein the tilt is approximately 50%.

63. (Previously Presented) The method of claim 49, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is provided at a rate of between approximately 20 and approximately 120 stimuli/minute.

Appl. No. 10/011,860

Amdt. AF dated May 6, 2005

Reply to Final Office Action of March 9, 2005

64. (Original) The method of claim 63, wherein the monophasic waveform is provided after a patient's heart rate is equal or less than approximately 20 beats/minute.

65. (Original) The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the third and fifth ribs.

66. (Original) The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the fourth and sixth ribs.

67. (Original) The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the sixth and eighth ribs.

68. (Original) The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the eighth and tenth ribs.

69. (Original) The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the tenth and twelfth ribs.